Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Timothy L Comstock"'
Publikováno v:
Clinical Ophthalmology, Vol 2011, Iss default, Pp 177-186 (2011)
Timothy L Comstock1 Michael R Paterno1 Angele Singh1 Tara Erb1 Elizabeth Davis21Bausch and Lomb Inc., Rochester, NY, USA; 2Minnesota Eye Consultants, Bloomington, MN, USABackground: To compare the safety and efficacy of loteprednol etabonate ophthalm
Externí odkaz:
https://doaj.org/article/ab92cd3cc6ee4e779872febd40028976
Publikováno v:
Clinical Ophthalmology, Vol 2010, Iss default, Pp 215-225 (2010)
Timothy L Comstock1, Paul M Karpecki2, Timothy W Morris3, Jin-Zhong Zhang41Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc., Rochester, NY, USA; 2Koffler Vision Group, Lexington, KY, USA; 3Research and Development Microbiology and Steri
Externí odkaz:
https://doaj.org/article/558707f1c679417aa2490cd37df17be9
Autor:
Radhika Tandon, Umang Mathur, Parul Sony, Timothy W. Morris, Timothy L. Comstock, Prashant Garg
Publikováno v:
Asia-Pacific Journal of Ophthalmology. :1-6
PURPOSE To evaluate the efficacy of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% in the treatment of bacterial conjunctivitis in an Indian population. DESIGN Multicenter, randomized, double-masked, activ
Autor:
Timothy L Comstock, Heleen H. DeCory
Publikováno v:
Ocular Immunology and Inflammation. 25:267-274
Purpose: To compare the efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) and dexamethasone 0.1%/tobramycin 0.3% (DM/T) ophthalmic suspensions in reducing select signs of blepharitis.Methods: Data were pooled from two studies (one from th
Publikováno v:
Ophthalmology and Therapy
Introduction The fluocinolone acetonide (FA) intravitreal implant 0.59 mg (Retisert®, Bausch + Lomb, Rochester, NY, USA) provides sustained release of FA directly to the vitreous cavity over a prolonged period of time. The purpose of this study was
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Pterygium, a sun-related eye disease, presents as wing-shaped ocular surface lesions that extend from the bulbar conjunctiva onto the cornea, most commonly on the nasal side. Pterygia show characteristic histological features that suggest that inflam
Publikováno v:
Advances in Therapy. 30:907-923
We aimed to evaluate the safety and efficacy of loteprednol etabonate (LE) gel 0.5% compared with vehicle in the treatment of postoperative inflammation and pain following cataract surgery, using the integrated analysis of data from two identical, pr
Autor:
Lynne S. Gearinger, Jesse DeLeon, Kirk Bateman, Bruce E. Silverstein, Timothy L. Comstock, Catherine Allaire, Timothy W. Morris
Publikováno v:
Clinical Drug Investigation. 32:303-317
Background and Objective: Besifloxacin ophthalmic suspension 0.6% given thrice daily for 5 days is safe and effective in the treatment of patients with bacterial conjunctivitis. This study evaluated the safety and efficacy of besifloxacin ophthalmic
Publikováno v:
Pediatric Drugs. 14:119-130
Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (LE/T) is indicated for steroid-responsive inflammatory ocular conditions where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. LE/T was shown
Autor:
Heleen H DeCory, Timothy L. Comstock
Publikováno v:
International Journal of Inflammation
International Journal of Inflammation, Vol 2012 (2012)
International Journal of Inflammation, Vol 2012 (2012)
Topical corticosteroids are effective in reducing anterior segment inflammation but are associated with adverse drug reactions (ADRs) including elevation of intraocular pressure (IOP) and cataract formation. Retrometabolic drug design has advanced th